MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer

MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer

Abstract Background Resistance to endocrine therapy is a major clinical challenge in the management of oestrogen receptor (ER)-positive breast cancer. In this setting, p53 is frequently wildtype and its activity may be suppressed via upregulation of its key regulator MDM2. This underlies our rationa...

Full description

Bibliographic Details
Main Authors: Neil Portman, Heloisa H. Milioli, Sarah Alexandrou, Rhiannon Coulson, Aliza Yong, Kristine J. Fernandez, Kee Ming Chia, Ensar Halilovic, Davendra Segara, Andrew Parker, Sue Haupt, Ygal Haupt, Wayne D. Tilley, Alex Swarbrick, C. Elizabeth Caldon, Elgene Lim
Format: Article
Language:English
Published: BMC 2020-08-01
Series:Breast Cancer Research
Subjects:
Breast cancer
MDM2
Oestrogen receptor
CDK4/6 inhibitor
p53
Online Access:http://link.springer.com/article/10.1186/s13058-020-01318-2

Internet

http://link.springer.com/article/10.1186/s13058-020-01318-2

Similar Items